Erelzi®
etanercept

Patient Card

SANDOZ A Novartis Division

NOVARTIS

This Patient Card contains important safety information that you need to be aware of before you are given Erelzi and during treatment with Erelzi. Please ask your doctor if you do not understand this information.

- Show this card to any doctor involved in treating you.
- See also Erelzi package leaflet for more information.

Infections

Erelzi may increase the risk of getting infections, which could be serious.

- You should not be treated with Erelzi if you have an infection. If you are not sure, ask your doctor.
- If you develop symptoms suggestive of infection, such as fever, persistent cough, weight loss or listlessness, seek medical attention immediately.
- You should be evaluated for tuberculosis (TB). Ask your doctor to record the dates and results of your last screening for TB below:

Test: _____

Date: _____

Results: _____

Test: _____

Date: _____

Results: _____

- Please ask your doctor to list your other medications that may increase your risk of infection.

Congestive Heart Failure

If you develop symptoms **suggestive of congestive heart failure or worsening of existing congestive heart failure,** such as shortness of breath, swelling of ankles, persistent cough or fatigue, seek medical attention immediately.

Other information (please complete):

Patient's name: _____

Doctor's name: _____

Doctor's phone number: _____

Keep this card with you during your treatment with Erelzi and for 2 months after the last Erelzi dose, since side effects may occur after your last dose of Erelzi.

It is important that you and your doctor record the brand name and batch number of your medication.

▼ This medicinal product is subject to additional monitoring. If you get any side effects, talk to your doctor, pharmacist or nurse. By reporting side effects, you can help provide more information on the safety of this medicine. You can report side effects directly via HPRA Pharmacovigilance Website: www.hpra.ie Side effects could also be reported to Novartis preferably via www.report.novartis.com, or by email to drugsafety.dublin@novartis.com or by calling 01 2080 612.

Date of Preparation: July 2021 | IE142207
HPRA approved October 2021